675 McDonnell Boulevard
About Mallinckrodt PharmaceuticalsMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.
Founder: Emil Mallinckrodt
CEO: Mark Trudeau
CFO: Matthew Harbaugh
Please click here for Mallinckrodt job opportunities.
262 articles with Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals, a leading global specialty pharmaceutical company, will present on Tuesday, March 12, 2019, at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel, 1601 Collins Ave, Miami Beach, Fla.
Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA)
Open-label phase of study completed; primary end point results consistent¹ with prior reports (n=116) that showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks
Mallinckrodt Pharmaceuticals announced today that it will report fourth quarter and fiscal 2018 earnings results for the period ending Dec. 28, 2018, on Tuesday, Feb. 26, 2019.
Data on Use of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation
First analysis to evaluate H.P. Acthar Gel for focal segmental glomerular sclerosis (FSGS) in kidney transplant recipients
-- Drug being evaluated for improved functional outcomes and survival rates for patients resuscitated after a cardiac arrest --
Mallinckrodt Pharmaceuticals will present on Monday, Jan. 7, 2019, at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Union Square, 335 Powell St., San Francisco.
Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)
Tablets for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The rejection comes about a month after the painkiller was cleared by an FDA advisory committee.
Shares of Mallinckrodt PLC are down nearly 2 percent in morning trading after the company announced it will spin off a new company that includes its specialty generics business to shareholders by the second half of 2019.
Transaction expected to create two differentiated pharmaceutical companies with scale - One focused on innovative specialty pharmaceutical brands; One with a portfolio of niche specialty generic products, active pharmaceutical ingredients (APIs), and non-promoted brands including the AMITIZA® product
Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)
-- Committees Vote to Approve Drug with Abuse-Deterrent Labeling --
Mallinckrodt Pharmaceuticals will present on Wednesday, Dec. 12, 2018, at the BMO Prescriptions for Success Healthcare Conference at the Mandarin Oriental, 80 Columbus Circle, New York.
The Food and Drug Administration is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for COPD, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look.
In Post-Hoc Pooled Analysis of North American Studies, Investigational Agent Terlipressin Associated With Improvement in Survival in Patients with Hepatorenal Syndrome Type 1 with Low Baseline Mean Arterial Pressure
Mallinckrodt Earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) Certifications for INOmax® DSIR® Plus Nitric Oxide Delivery Systems
Achievements Indicate Mallinckrodt Meets Standards and Regulations Among the Most Comprehensive for Medical Device Quality Management Systems
Net sales of $640.0 million, up 6.6%, or 6.7% on a constant-currency basis
Mallinckrodt plc today announced the addition of a new member to its Scientific Advisory Council (SAC).
First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Mallinckrodt plc today confirmed screening of the first patient in the company's Phase 4, multi-center, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as a therapy option in patients with Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU).
Mallinckrodt and the Lupus Foundation of America Present Data from Survey of Over 1,500 Individuals with Self-Reported Lupus at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting
Study finds individuals with lupus experience a high disease flare burden and as a result engage in preventive and treatment measures
Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting
Phase 4 study interim analysis showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks